Last updated: July 1, 2026
Galderma Laboratories LP v. Teligent Inc. 3:15-cv-03876: Litigation Summary, Patent/ANDA Posture, and Exclusivity Risk
Executive summary
The docket 3:15-cv-03876 is a patent infringement case by Galderma Laboratories LP against Teligent Inc. tied to ANDA-related generic entry for a Galderma-branded dermatology product. The dispute’s practical impact is binary for generic timing: if Galderma’s asserted claims hold (direct infringement and validity), Teligent’s launch is blocked; if claims are narrowed or invalidated, entry timing shifts to the next carve-out around expiration dates, exclusivity, and any design-around.
Key litigation elements typically present in an ANDA patent case are: Galderma’s Orange Book listed patents are asserted against Teligent’s ANDA manufacture/use; Teligent generally responds with non-infringement and invalidity defenses; courts resolve claim scope, infringement, and validity; and any settlement can impose effective market-entry dates.
However, the provided docket identifier alone does not include the necessary record-level information to produce a complete, accurate, citation-grade litigation summary (asserted patent numbers, complaint date, PI/temporary injunction outcomes, PTAB activity, claim construction rulings, trial/judgment posture, or any settlement terms). Under strict completeness requirements, a reliable summary cannot be generated from the case caption/number alone.
What is the 3:15-cv-03876 Galderma v. Teligent litigation about?
Short answer: A Galderma patent infringement suit against Teligent arising from Teligent’s ANDA submission for a Galderma dermatology drug with Orange Book patents.
What claims are usually asserted in Galderma v. Teligent ANDA cases
Common asserted categories in Galderma-led ANDA litigations include:
- Composition/formulation claims (active concentration, excipients, stability, delivery vehicle)
- Method-of-use claims (indication-directed use regimens)
- Manufacturing/process claims (preparation steps that impact product characteristics)
What product and patents are typically tied to the Orange Book listing
In ANDA patent litigations, the brand company asserts only those patents that are listed in the Orange Book for the reference listed drug. The litigation record typically contains:
- The RLD name
- The ANDA applicant
- The Orange Book patent list
- The asserted patent subset
- The Teligent certification(s) (usually Paragraph IV, but the complaint specifies what was filed)
Which patents protect the Galderma drug in Galderma Laboratories LP v. Teligent Inc (3:15-cv-03876)?
Short answer: The asserted patents are identified in the complaint and follow-on claim charts.
Where to confirm the exact asserted patents
The correct patent numbers, expiration dates, and owners must be taken from:
- The complaint (asserted claims/patents)
- The Amended Complaints (if any)
- The scheduling order and claim construction filings
When does Galderma’s exclusivity end in the 3:15-cv-03876 dispute?
Short answer: Exclusivity timing depends on the RLD’s regulatory exclusivities (30-month stay triggers, pediatric exclusivity if applicable, and any orphan or Hatch-Waxman related stays), plus the earliest patent expiration among asserted and Orange Book-listed patents.
What courts look at for timing
- Patent expiration of the asserted Orange Book patents
- Whether the case reaches final judgment before any expiry
- Whether settlement modifies entry date
- Whether any additional patents are asserted later in subsequent amendments
What is the Orange Book status of the Galderma drug at issue in 3:15-cv-03876?
Short answer: The Orange Book status is defined by:
- Listed patent set
- Patent expiration and exclusivity end dates
- The specific Teligent certification for the ANDA
How to interpret typical Orange Book entries in these cases
A full analysis requires mapping:
- Patent type (drug substance, formulation, method, device, manufacturing)
- Listed expiration date
- Whether the patent is subject to exclusivity extensions
Did Teligent file a Paragraph IV certification in 3:15-cv-03876?
Short answer: ANDA litigations in this pattern typically involve a Paragraph IV certification, but the exact certification status must be taken from the complaint and answer.
What matters for the 30-month stay
- Filing date of the ANDA
- Date of Paragraph IV notice
- Triggering of the 45/30-month procedural timelines
- Any court stays, consent judgments, or settlement-driven modifications
How strong is Galderma’s patent estate versus Teligent’s defenses in 3:15-cv-03876?
Short answer: Strength is measured by the court’s handling of:
- Claim construction
- Infringement proof (product comparison and technical evidence)
- Validity defenses (anticipation, obviousness, written description/enablement)
What “strength” usually looks like in the record
A defensible “strength” score requires:
- Asserted claim construction outcomes
- Summary judgment rulings on infringement/invalidity
- Trial or final judgment posture
- Any Federal Circuit history if appealed
What did the court decide in Galderma v. Teligent (3:15-cv-03876)?
Short answer: The decision depends on claim construction and any final disposition (dismissal, summary judgment, or post-trial judgment). These details are not present in the docket number alone.
What a litigation summary must include (record-level)
- Complaint filing date and asserted patents
- Constructions for each disputed claim term
- Infringement findings or non-infringement holdings
- Validity findings (each defense)
- Whether an injunction issued
- Whether there is a settlement and its terms
Was there a settlement in 3:15-cv-03876, and what does it mean for launch timing?
Short answer: Settlement terms, if present, can shift launch dates via:
- “Go-live” or delayed-entry agreements
- License grants or covenant-not-to-sue
- Dismissal with agreed effective dates
What to quantify in a settlement
A proper analysis would specify:
- Effective date
- Earliest permitted launch
- Any carve-outs for additional strengths/dosage forms
- Ongoing litigation scope (dismissed vs. reserved patents)
What generic entry risks exist for Teligent after 3:15-cv-03876?
Short answer: Remaining risk depends on any unasserted patents, later Orange Book additions, and whether the final judgment limits only the asserted claims or the broader patent family.
Typical post-judgment risk vectors
- Other Orange Book patents for the same RLD not asserted in the case
- Continuation patents or related family members
- Device/delivery platform patents, if the product uses a novel vehicle
- Design-around freedom vs. risk of equivalence
How does Galderma’s litigation posture compare with other dermatology ANDA fights?
Short answer: The case likely follows the standard playbook for Hatch-Waxman patent litigations, with the outcome driven by claim scope and validity analysis rather than broad industry narrative.
What comparative analysis requires
To compare estates and outcomes, the analysis must include:
- Asserted patent list and expiration timing
- Federal court outcomes
- Settlement entries and launch timing
Key Takeaways
- The case is an ANDA-linked patent infringement suit by Galderma against Teligent under 3:15-cv-03876.
- Launch timing turns on asserted patents and the court’s final resolution of infringement and validity.
- A complete litigation summary requires asserted patent numbers, court rulings, and final disposition, none of which are contained in the docket identifier alone.
FAQs
- What patents does Galderma assert in 3:15-cv-03876 and what are their expiration dates?
- Does the case involve a Paragraph IV certification and what 30-month stay timeline applied?
- What claim construction rulings affected infringement in the Galderma v. Teligent litigation?
- Did the court issue an injunction or did the parties settle, and on what go-live date?
- After final judgment, what additional Orange Book patents could still block Teligent’s ANDA launch?
References
- U.S. District Court, Federal Docket (case number 3:15-cv-03876), Galderma Laboratories LP v. Teligent Inc.
